Recombinant DNA technology offers profound advantages, notably the ability to engineer highly specific biotherapeutics—such as monoclonal and multi-specific antibodies—with unprecedented purity, target affinity, and scalability.
However, these capabilities come with distinct disadvantages and development bottlenecks. The biological complexity of engineering foreign genetic material often introduces instability, low expression yields, and severe aggregation risks, particularly in non-standard formats.
Mitigating these technical hurdles requires moving beyond rudimentary expression systems and relying on highly optimized mammalian platforms, ensuring that the theoretical advantages of rDNA translate reliably into viable clinical candidates.
The table below summarises the main pros and cons of recombinant DNA technology at a glance.
| Aspect | Advantages | Disadvantages |
|---|---|---|
| Therapeutics | Enables highly specific biologics such as monoclonal and bispecific antibodies | Complex formats can suffer from instability, low yields, and aggregation |
| Production | Consistent, scalable supply independent of donor or animal sources | Requires optimised expression systems; bacterial hosts fail for complex proteins |
| Agriculture | Crops with improved resistance to pests and harsh conditions | Public concern over releasing genetically modified organisms |
| Research | Precise engineering of proteins with defined properties | Ethical debate over modifying genetic material |
| Society | Gene therapies for hereditary diseases | Access inequality and intellectual property questions over DNA sequences |
Recombinant DNA – a definition
Recombinant DNA, in short rDNA, denotes any piece of DNA that results from artificial combinations of DNA segments, in particular genetic material of different species in vitro (“in test tubes”).
In 1974, the Stanford University filed a patent application concerning recombinant DNA, listing S. N. Cohen and H. W. Boyer as the inventors. Paul Berg received the 1980 Nobel Prize in chemistry for his studies “with particular regard to recombinant DNA”1,2
Since DNA sequences contain the molecular blueprints for transcription of mRNA which defines the amino acid sequence for protein synthesis (gene expression), molecular cloning of bacterial plasmids, amplification using polymerase chain reaction (PCR) and insertion into living cells allows scientists to design and produce novel proteins.
The development of restriction enzymes such as restriction endonucleases to create DNA strands capable of taking up foreign genetic material allowed to confer e.g. antibiotic resistance or promoter regions to enhance transcription. Subsequent joining of the strands with DNA ligase led to recombinant plasmids that could be inserted into host cells to perform DNA replication and further use in recombinant DNA research.
The next step was to move this technology from bacterial cells such as Escherichia coli (E. coli) to eukaryotic cells: plants and animals, allowing the laboratory production of medically relevant recombinant proteins like human growth hormone and human insulin to treat diseases.
Recombinant DNA technology – Disadvantages
Recombinant DNA technology received a lot of negative media coverage in the early 2000s, when transgenic plants were marketed in the U.S. and a public discussion of its ethical, economical, social, intellectual property and religious implications ensued:
- Ethics: Should mankind have and use the means to modify to their own nucleic acids for enhancing themselves? What are the risks of bringing out genetically modified organisms into our environment?
- Economics: Should companies be allowed to perform recombinant DNA and RNA research and market their resulting products?
- Society: Will underprivileged people become further disadvantaged without access to biotechnology products?
- Intellectual property of DNA fragments and the human genome: Are people owners of the nucleotide sequence that defines their body? Can people or companies claim intellectual property of genetically modified organisms?
- Religion: Is mankind allowed to create new or modify existing lifeforms?
Some of these topics were considered verging on science-fiction, but several have become reality, e.g. in the form of gene therapies. Ethical and religious implications are still debated heatedly.
On the technical side, recombinant expression of complex proteins remains demanding. Foreign genetic material can fold incorrectly, express at low yields, or aggregate, and these effects are most pronounced in engineered formats such as scFv-based or bispecific constructs. Bacterial systems cannot perform the post-translational modifications these molecules require, which is why mammalian platforms such as CHO cells are used.
Recombinant DNA technology – Advantages
Recombinant DNA technology has many advantages. Weighing the pros and cons of recombinant DNA technology, the benefits clearly dominate in medicine and agriculture, and rDNA and its applications are present in everyday life:
- increased resistance of crop plants to harsher environmental conditions or pests
- innovative medical and pharmaceutical research to develop new therapeutics
- genetic engineering of recombinant DNA molecules coding for useful proteins, e.g. therapeutic peptide hormones, therapeutic monoclonal antibodies
- development and insertion of DNA therapeutics (gene therapies) into damaged chromosomes to treat hereditary diseases
These applications have a huge positive impact on our everyday lives and countless patients, even though many of us do not know about them.
Conclusion – why rDNA is the future
While recombinant DNA technology has fundamentally reshaped agriculture and environmental sciences, its most profound impact remains in the life sciences and therapeutic antibody development. The transition from crude bacterial cloning to highly optimized, transient CHO expression has removed historical bottlenecks in protein engineering.
For drug developers, the future of rDNA is about speed without the sacrifice of quality. Whether rapidly screening AI-generated sequences or expressing highly engineered bispecifics, leveraging a dedicated recombinant antibody production service partner like evitria de-risks the pipeline. By generating early, reliable data in the exact CHO platform used for eventual pre-clinical scaling, researchers can rely on evitria’s specialized expertise to confidently advance their most promising candidates to market.
FAQs on the pros and cons of recombinant DNA technology
The main pros are the ability to produce therapeutic proteins such as insulin, peptide hormones, and monoclonal or bispecific antibodies, crops with improved resistance, and gene therapies for hereditary diseases. The main cons are technical, including instability, low expression yields, and aggregation in complex formats, alongside ethical, economic, and intellectual property debates.
Recombinant DNA technology allows proteins to be produced consistently and at scale, without relying on donor or animal sources. It underpins therapeutic antibodies, peptide hormones, vaccines, gene therapies, and crops that resist pests and harsh conditions.
Technically, foreign genetic material can fold incorrectly, express at low yields, or aggregate, particularly in engineered formats such as scFv-based or bispecific constructs. Beyond the laboratory, the technology raises ethical, economic, societal, and intellectual property questions that are still debated.
In medicine and agriculture the benefits clearly dominate, since rDNA delivers therapies and crops that would otherwise not exist. The technical hurdles are real but manageable with optimised mammalian expression platforms, while the ethical questions remain a matter of ongoing public debate.
Sources
- 1.The Nobel Prize in Chemistry 1980. The Nobel Prize. Accessed December 2022. https://www.nobelprize.org/prizes/chemistry/1980/summary/
- 2.Jackson DA, Symons RH, Berg P. Biochemical Method for Inserting New Genetic Information into DNA of Simian Virus 40: Circular SV40 DNA Molecules Containing Lambda Phage Genes and the Galactose Operon of Escherichia coli. Proc Natl Acad Sci USA. Published online October 1972:2904-2909. doi:10.1073/pnas.69.10.2904